The estimated Net Worth of Jasbir Seehra is at least $14.8 Million dollars as of 8 April 2023. Dr Seehra owns over 4,000 units of Keros Therapeutics stock worth over $13,843,866 and over the last 6 years he sold KROS stock worth over $0. In addition, he makes $908,087 as Pres, CEO, Treasurer und & Director at Keros Therapeutics.
Sign up
Dr D KROS stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Keros Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of KROS stock worth $1,920 on 8 April 2023.
The largest trade he's ever made was buying 20,000 units of Keros Therapeutics stock on 13 April 2020 worth over $320,000. On average, Dr trades about 2,071 units every 78 days since 2018. As of 8 April 2023 he still owns at least 252,856 units of Keros Therapeutics stock.
You can see the complete history of Dr Seehra stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Jasbir Seehra Ph.D. biography
Dr. Jasbir Seehra Ph.D. is the Pres, CEO, Treasurer, & Director at Keros Therapeutics.
What is the salary of Dr D?
As the Pres, CEO, Treasurer und & Director of Keros Therapeutics, the total compensation of Dr D at Keros Therapeutics is $908,087. There are no executives at Keros Therapeutics getting paid more.
How old is Dr D?
Dr D is 65, he's been the Pres, CEO, Treasurer und & Director of Keros Therapeutics since . There are no older and 4 younger executives at Keros Therapeutics.
What's Dr D's mailing address?
Jasbir's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Insiders trading at Keros Therapeutics
Over the last 5 years, insiders at Keros Therapeutics have traded over $50,765,607 worth of Keros Therapeutics stock and bought 2,504,088 units worth $46,191,339 . The most active insiders traders include Ran Nussbaum, Carl L Gordon und Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $3,312,649. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth $11,002,500.
What does Keros Therapeutics do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
What does Keros Therapeutics's logo look like?
Complete history of Dr Seehra stock trades at Eloxx Pharmaceuticals Inc und Keros Therapeutics
Keros Therapeutics executives and stock owners
Keros Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Jasbir Seehra Ph.D.,
Pres, CEO, Treasurer, & Director -
Dr. Jennifer Lachey Ph.D.,
Chief Scientific Officer -
Keith C. Regnante,
Chief Financial Officer -
Christopher Rovaldi M.Sc.,
Chief Operating Officer -
Dr. Simon Cooper MBBS,
Chief Medical Officer -
Robin Wagner,
VP of HR -
Esther Cho J.D.,
Head of Legal & Corp. Sec. -
Julius Knowles,
-
Tomer Kariv,
-
Carl L Gordon,
Director -
Ran Nussbaum,
-
Nima Farzan,
-
Tomer Pontifax (Israel) Iv,...,
-
Mary Ann Gray,
-
Ran Pontifax (Israel) Iv, L...,
-
Alpna Seth,
-
Keith Regnante,
CHIEF FINANCIAL OFFICER -
Jasbir Seehra,
CHIEF EXECUTIVE OFFICER -
Christopher Rovaldi,
CHIEF OPERATING OFFICER -
Jennifer Lachey,
Chief Scientific Officer -
Claudia Ordonez,
Chief Medical Officer -
Alon Lazarus,
Director -
Advisors Llc Orbi Med Capit...,
-
Management 4 G.P. (2015) Lt...,
-
Bio Ventures Limited Partne...,
-
Simon Peter Cooper,
CHIEF MEDICAL OFFICER -
Jean Jacques Bienaime,